Research News
View articles by month and year
-
Accelerated Radiation May Be as Good as Standard Schedule to Lower DCIS Recurrence Risk
Research suggests that a shorter, higher-dose radiation schedule after lumpectomy to remove DCIS may reduce recurrence risk just as much as a standard radiation treatment schedule.
-
Afinitor Approved to Treat Advanced-Stage, Hormone-Receptor-Positive Disease
Afinitor has been approved to be used in combination with Aromasin to treat advanced-stage, hormone-receptor-positive, HER2-negative breast cancer in postmenopausal women that has already been treated with Femara or Arimidex.
-
Aromatase Inhibitors Seem Less Effective in Obese Women
A small study found that while obese women diagnosed with early-stage, hormone-receptor-positive breast cancer who took Arimidex and Femara had lower estrogen levels than before they started treatment, their estrogen levels were still more than double those of women at a healthy weight.
-
About 20% of Women Need More Surgery After Lumpectomy
A British study has found that about 20% of women who have lumpectomy have to have more surgery once their doctors have all the information about the cancer and breast tissue that was removed.
-
Large Review Study Says Avastin Offers Only Modest Benefits for Metastatic Breast Cancer
Results from a new large review study show that Avastin offers only modest benefits for stopping the growth and spread of metastatic breast cancer.
-
Daily Exercise – At Any Intensity Level – May Lower Risk
A study has found that women who got about 2 hours of exercise each day -- at any intensity level -- were about 30% less likely to develop breast cancer than women who didn't exercise that much.
-
Mammogram Rates Have Dropped After Task Force Recommendation
A study found that fewer women in their 40s are getting screening mammograms since the U.S. Preventive Services Task Force recommended that screening mammograms start at age 50 instead of 40.
-
FDA Advisory Panel Approves MarginProbe System
An FDA expert panel voted to approve the MarginProbe system - a device that helps surgeons decide if all the cancer tissue has been removed during lumpectomy.
-
Experimental Vaccine May Help Reduce Recurrence Risk of HER2-Positive Disease
A new study has found that an experimental vaccine targeting HER2-positive breast cancer cells lowered the risk of the cancer coming back in women diagnosed with HER2-positive, early-stage breast cancer.
-
Perjeta Improves Overall Survival in HER2-Positive, Metastatic Disease
More results from the CLEOPATRA study show that women who got Perjeta, Herceptin, and Taxotere had better overall survival than women who got only Herceptin and Taxotere.
